The British public is being fed a comforting lie. We are told that the National Health Service (NHS) is a master negotiator, a David standing up to the Goliath of "Big Pharma" to keep drug prices low and access high. The reality is far uglier. The UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) isn't a victory for the taxpayer; it is a sophisticated suicide note for the country's life sciences sector and a slow-motion disaster for patient outcomes.
We obsess over the "transatlantic tussle" between the UK’s cost-effectiveness thresholds and the US’s free-market chaos. But we are asking the wrong question. It’s not about who pays less. It’s about why the UK has decided that being the cheapest is more important than being the best. For an alternative perspective, see: this related article.
The Myth of the "Reasonable" Rebate
The lazy consensus suggests that the current VPAS—which requires pharmaceutical companies to pay back a percentage of their revenue to the government if the total NHS medicine spend grows beyond a certain limit—is a "fair share" mechanism.
It isn't. It’s a tax on success. Related reporting on the subject has been published by World Health Organization.
In 2023, the rebate hit a staggering 26.5%. Imagine running a business where, if you innovate too well and too many people need your product, the state takes back a quarter of your revenue, not your profit. This isn't "synergy" or "partnership." It’s a shakedown. When you cap the total spend regardless of the clinical value delivered, you aren't saving money. You are telling global CEOs to build their labs in Boston, Singapore, or Munich instead of Cambridge or Manchester.
I’ve sat in rooms where executives look at the UK market and simply check out. They don't see a "world-class health system." They see a rounding error with a hostile accounting department.
NICE and the QALY Trap
The National Institute for Health and Care Excellence (NICE) uses the Quality-Adjusted Life Year (QALY) to decide if a drug is worth it. For decades, the threshold has sat stubbornly between £20,000 and £30,000.
Think about that. While inflation has eroded the value of the pound, and the complexity of gene therapies has skyrocketed, the UK’s valuation of a year of healthy life has remained largely frozen. We are trying to buy 2026 medicine with 2004 pocket change.
The "contrarian" truth? Low drug prices are a false economy. When you suppress prices to the point of extinction, you get:
- Delayed Access: The UK often gets life-saving drugs 12 to 18 months after the US or Germany.
- Clinical Trial Flight: If a drug won't be used in the local market, why run the trial here?
- Brain Drain: Our best researchers are following the capital.
The US Isn't the Enemy—It's the Life Support
British commentators love to sneer at the "exorbitant" prices in the United States. They argue that the US "subsidizes" the rest of the world’s R&D.
They are right. But they say it like it’s a bad thing for us.
If the US ever adopted a UK-style pricing model, global pharmaceutical R&D would vanish overnight. The high margins in the US market fund the high-risk, high-cost failures that define drug discovery. The UK is essentially a "free rider" on American innovation, then has the audacity to complain when the newest oncology breakthroughs aren't offered for the price of a generic ibuprofen.
However, the ride is ending. The US Inflation Reduction Act (IRA) is beginning to squeeze margins stateside. As the US market becomes less profitable, pharmaceutical companies will no longer be able to "absorb" the losses forced upon them by the NHS. The "tussle" is over. The UK is losing.
The Misconception of "Drug Spend"
The most pervasive lie in the NHS is that "drugs are too expensive."
Medicines account for roughly 10% to 15% of the total NHS budget. The other 85%? Staffing, crumbling infrastructure, and the massive cost of "waiting."
If a new drug costs £100,000 but keeps a patient out of a hospital bed that costs £1,000 a night, prevents surgery, and allows that patient to return to work and pay taxes, the drug is a bargain. But the NHS budget is siloed. The pharmacy budget is separate from the hospital bed budget. The "system" cannot see the forest for the trees. It would rather save £10,000 on a drug price today than save £100,000 in social care costs tomorrow.
The "Innovative" New Scheme (VPAG) is Just VPAS with a Fancy Hat
The successor to VPAS, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), promises a "sustainable" path. It claims to distinguish between "innovative" medicines and older ones.
Don't be fooled. The fundamental mechanic remains the same: an arbitrary cap on growth.
If we have a sudden breakthrough in Alzheimer’s treatment—a disease that costs the UK economy billions—the VPAG mechanism would essentially punish the companies that solved the problem because the "total spend" would spike. We are literally disincentivizing the cure for the most expensive diseases in our society.
Why You’re Asking the Wrong Question
You might ask: "How do we make drugs more affordable for the NHS?"
That is the wrong question. The right question is: "How do we make the NHS productive enough to afford the best medicine in the world?"
We treat the NHS budget like a fixed pie. It isn't. The economy is supposed to grow. If your healthcare system is so focused on "cost-cutting" that it stifles the Life Sciences sector—one of the UK's few remaining global competitive advantages—you are shrinking the very economy that funds the NHS.
It is a death spiral.
The Brutal Truth for Patients
If you have a rare disease in the UK, you are a second-class citizen. You are at the mercy of a "cost-effectiveness" spreadsheet that doesn't account for your individual humanity.
I’ve seen patient groups beg for access to drugs that are standard of care in France or Japan. They are told "the data isn't robust enough" or "the price isn't right." Translation: "We’ve decided your life isn't worth the rebate we’d lose."
How to Actually Fix the Mess
We need to stop the "us vs. them" rhetoric with the industry.
- Abolish the Revenue Cap: Move to an outcomes-based model. Pay for what works. If a drug doesn't deliver the promised clinical result in a real-world NHS setting, the company doesn't get paid. This shifts the risk from the taxpayer to the manufacturer.
- Scrap the QALY for Rare Diseases: You cannot apply the same math to a common blood pressure pill and a one-time gene therapy for a child with a terminal condition. It’s intellectually dishonest and morally bankrupt.
- Merge the Budgets: Allow the NHS to track the "Total Cost of Care." If a drug reduces the need for nurses and beds, the pharmacy budget should be credited.
- End the Free Ride: Accept that if we want a seat at the table of global innovation, we have to pay the entry fee.
The UK life sciences sector is at a breaking point. AstraZeneca is building in Ireland. GSK is looking elsewhere. The "transatlantic tussle" isn't a fight for fairness; it's a fight for survival.
Stop cheering for "lower prices." You are cheering for the decline of British medicine and the eventual rationing of your own care.
The NHS isn't "saving" money on drugs. It's mortgaging the health of the next generation to balance a spreadsheet today.
Stop asking for cheaper drugs. Start demanding a system that can afford to keep you alive.
